Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: Considerations for their appropriate use to avoid serious adverse events

Expert Opinion on Drug Safety

Volumn 14, Issue 6, 2015, Pages 795-800

  Yabe, Daisuke ^a,b   Nishikino, Rie ^c   Kaneko, Makiko ^c   Iwasaki, Masahiro ^a   Seino, Yutaka ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Japan Medical Data Center   (Japan)

Author keywords

Dehydration; Hypoglycemia; Serious adverse events; Sodium glucose co transporter 2 inhibitors; Urogenital infections

Indexed keywords

ALOGLIPTIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; FATTY ACID; GLUCAGON; GLYCEROL; GLYCOGEN; INSULIN; IPRAGLIFLOZIN; KETONE BODY; LUSEOGLIFLOZIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TOFOGLIFLOZIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SODIUM GLUCOSE COTRANSPORTER 2;

BRAIN INFARCTION; CARBOHYDRATE DIET; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DATA BASE; DEHYDRATION; DIABETIC KETOACIDOSIS; DRUG ERUPTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECZEMA; ERYTHEMA; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GLUCOSURIA; GLUCOTOXICITY; GLYCEMIC CONTROL; GLYCOGEN LIVER LEVEL; GLYCOGENOLYSIS; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; JAPAN; KETOGENESIS; LIPOLYSIS; META ANALYSIS (TOPIC); MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSMOTIC DIURESIS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PATIENT SAFETY; PROTEIN DEGRADATION; RASH; REVIEW; SARCOPENIA; SCREENING; SHORT COURSE THERAPY; SKIN MANIFESTATION; SUBCUTANEOUS TISSUE; UROGENITAL TRACT INFECTION; URTICARIA; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; SECRETION (PROCESS); TIME;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS;

EID: 84929584388     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1034105     Document Type: Review

References (15)

1. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig 2014;5(3):265-75 .. A comprehensive review article describing efficacy and safety of sodium/glucose co-transporter 2 inhibitors (SGLT2i) based on results of clinical trials.
2. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2014;104(3):297-322
3. Tauchi K. 10 deaths reported following use of newly marketed diabetes drugs. Available from: http://ajw.asahi.com/article/sci-tech/medical/AJ201501090058 [Last accessed 17 January 2015]
4. Hoffman KB, Dimbil M, Erdman CB, et al. The Weber effect and the United States food and drug administration's adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug safety 2014;37(4):283-94
5. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-Analysis. Ann Intern Med 2013;159(4):262-74 . A systematic review article demonstrating efficacy and safety of SGLT2i based on results of clinical trials.
6. Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabet Investig 2014;5(5):475-7 . An editorial article describing mechanisms underlying severe hypoglycemia in patients receiving DPP-4i and sulfonylureas, and recommendations from experts in Japan released to prevent such adverse events.
7. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124(2):499-508 .. An original article demonstrating the metabolic response to SGLT2i in individuals with type 2 diabetes and discussing potential risks of chronic SGLT2i use.
8. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104(6):787-94
9. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012;122(1):4-12
10. Yabe D, Kuroe A, Watanabe K, et al. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. J Diabetes Complications 2015;29(3):413-21
11. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124(2):509-14 .. An original article demonstrating the metabolic response to SGLT2i in individuals with type 2 diabetes and discussing potential risks of chronic SGLT2i use.
12. Yabe D, Seino Y, Fukushima K, et al. b-cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Current Diabetes Report; doi: 10.1007/s11892-015-0602-9 . A comprehensive review article describing phenotype of East Asians' type 2 diabetes.
13. Dimitriadis G, Mitrou P, Lambadiari V, et al. Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract 2011;93(Suppl 1):S52-9
14. Ramnanan CJ, Edgerton DS, Kraft G, et al. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 2011;13(Suppl 1):118-25
15. Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol 2014;2(10):819-29